clinical trial · NCT07204340
TLN-372 in Advanced KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.·phase1·recruiting·n = 240
KRAS Mutant Solid TumorsTLN-372TLN-372 in combination with cetuximabTLN-372 in combination with pembrolizumab
brief summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
started
Sep 29, 2025
primary completion
Dec 3, 2031
completion
Apr 1, 2032
last updated
Apr 21, 2026
official title
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol